Pure Global

Understanding and Treating Traumatic Brain Injury (TBI) Associated Photophobia With Botulinum Toxin Type A (BoNT-A) - Trial NCT06293300

Access comprehensive clinical trial information for NCT06293300 through Pure Global AI's free database. This Phase 2 trial is sponsored by University of Miami and is currently Not yet recruiting. The study focuses on Traumatic Brain Injury. Target enrollment is 50 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.

Free Database
Powered by Pure Global AI
840K+ Trials
NCT06293300
Phase 2
Not yet recruiting
drug
Trial Details
ClinicalTrials.gov • NCT06293300
View on ClinicalTrials.gov
Pure Global
DJ Fang

DJ Fang

MedTech Regulatory Expert

Need help with 30+ markets registration?

Pricing
Understanding and Treating Traumatic Brain Injury (TBI) Associated Photophobia With Botulinum Toxin Type A (BoNT-A)
Understanding and Treating TBI Associated Photophobia With Botulinum Toxin Type A and Its Impact on Visual Function

Study Focus

Traumatic Brain Injury

BoNT A

Interventional

drug

Sponsor & Location

University of Miami

Miami, United States of America

Timeline & Enrollment

Phase 2

Aug 01, 2024

Aug 30, 2026

50 participants

Primary Outcome

Change in photophobia measured by Numerical Rating Scale,Change in visual photosensitivity thresholds (VPT) measured Ocular Photosensitivity Analyzer (OPA)

Summary

The purpose of this research is to understand and treat Traumatic Brain Injury (TBI)
 associated photophobia (light sensitivity) and its impact on visual function.

ICD-10 Classifications

Diffuse brain injury
Intracranial injury
Focal brain injury
Intracranial injury, unspecified
Other intracranial injuries

Data Source

ClinicalTrials.gov

NCT06293300

Non-Device Trial